Huntsman Announces Third Quarter 2026 Earnings

Huntsman reported Q3 2026 revenue of $1.717 billion, up 18% year over year, and adjusted EBITDA of $132 million versus $94 million; adjusted net income turned positive at $7 million, although the company recorded an $18 million net loss. Free cash flow declined to $82 million from $157 million, while management said improved results and cash flow are expected to bring net debt leverage to approximately 4 times by year-end. Shareholders approved the merger of equals with Olin, and Huntsman now expects it to close in Q1 2027, subject to remaining regulatory approvals.

Analysis

The earnings improvement looks operationally real but not yet cash-validated. Polyurethane pricing and margins are recovering, while Advanced Materials’ volume contribution offers a more durable signal; however, Performance Products’ revenue lift is largely price/mix rather than demand growth. If pricing mainly offsets higher feedstock and logistics costs, further top-line gains need not translate proportionally into earnings. The sharp year-to-date working-capital cash use, alongside higher net debt, makes the year-end deleveraging goal dependent on sustained cash conversion—not EBITDA alone. Verify receivables, inventory and payables trends on the call.

For HUN, near-term earnings momentum is supportive, but the merger adds a separate event-risk premium: remaining approvals, closing conditions and integration execution could delay or dilute any value realization. Olin exposure is not a clean hedge without the exchange terms and current deal spread. Over 6–18 months, improved MDI economics could also support comparable producers such as Covestro and BASF; a reversal in MDI pricing or weaker industrial demand would undermine that read-through. The contrarian point: the headline EBITDA rebound may overstate balance-sheet progress, while the quarter’s stronger operating performance may be more persistent than the cash-flow comparison suggests. No valuation or market-price data are provided, so avoid chasing a one-day earnings reaction.

Key Decisions for Investors

• Treat HUN as a cautious, catalyst-driven long rather than a standalone recovery conviction: consider entry only after the initial reaction, and require confirmation that segment margins hold as raw-material costs move. Falsify the thesis if subsequent results show margin reversal or renewed volume weakness.
• Keep merger-arbitrage exposure on watch, not as a recommendation: first verify the exchange ratio/consideration, current HUN–OLN deal spread, remaining jurisdictional approvals and closing conditions. Reassess if the expected first-quarter 2027 close slips or regulatory conditions change.
• Use the November 3 call to test cash quality: seek detail on working-capital normalization, debt reduction and the basis for the leverage forecast. A failure to convert operating earnings into cash would argue against adding HUN even if adjusted EBITDA remains firm.
• For chemicals exposure, monitor MDI pricing and supply-demand indicators against Covestro and BASF commentary; a broad pricing reversal would weaken the sector read-through and the HUN recovery case.